Literature DB >> 16873803

Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.

Giuseppe Papa1, Viviana Fedele, Maria Rosaria Rizzo, Marisa Fioravanti, Carmelo Leotta, Sebastiano Bruno Solerte, Francesco Purrello, Giuseppe Paolisso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16873803     DOI： 10.2337/dc05-2495

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  18 in total

1.  [Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes].

Authors:  Edelmiro Menéndez Torre; Francisco Javier Lafita Tejedor; Sara Artola Menéndez; Jesús Millán Núñez-Cortés; Angeles Alonso García; Manuel Puig Domingo; José Ramón García Solans; Fernando Alvarez Guisasola; Javier García Alegría; Javier Mediavilla Bravo; Carlos Miranda Fernández-Santos; Ramón Romero González
Journal:  Aten Primaria       Date:  2011-03-05       Impact factor: 1.137

2.  IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.

Authors:  Qiong Huang; Ji-ye Yin; Xing-ping Dai; Qi Pei; Min Dong; Zhi-guang Zhou; Xi Huang; Min Yu; Hong-hao Zhou; Zhao-qian Liu
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

Review 3.  Repaglinide: a review of its use in type 2 diabetes mellitus.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

4.  Diabetes in an older woman living in a long-term care residence.

Authors:  Daniel M Tessier; Graydon S Meneilly
Journal:  CMAJ       Date:  2014-08-18       Impact factor: 8.262

5.  NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.

Authors:  Zhi-Cheng Gong; Qiong Huang; Xing-Ping Dai; Guang-Hua Lei; Hong-Bin Lu; Ji-Ye Yin; Xiao-Jing Xu; Jian Qu; Qi Pei; Min Dong; Bo-Ting Zhou; Jie Shen; Gan Zhou; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

6.  Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.

Authors:  Qiong Huang; Ji-Ye Yin; Xing-Ping Dai; Jing Wu; Xiang Chen; Cai-Shu Deng; Min Yu; Zhi-Cheng Gong; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Eur J Clin Pharmacol       Date:  2010-08-31       Impact factor: 2.953

Review 7.  Antidiabetic oral treatment in older people: does frailty matter?

Authors:  Angela Marie Abbatecola; Giuseppe Paolisso; Andrea Corsonello; Silvia Bustacchini; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2009-12       Impact factor: 3.923

Review 8.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

Review 9.  Individualising therapy for older adults with diabetes mellitus.

Authors:  Danelle Cayea; Cynthia Boyd; Samuel C Durso
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  A prototype for evidence-based pharmaceutical opinions to promote physician-pharmacist communication around deprescribing.

Authors:  Philippe Martin; Cara Tannenbaum
Journal:  Can Pharm J (Ott)       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.